Ester Prodrugs of Cyclic 1-((S)-[3-Hydroxy-2-(phosphonomethoxy)propyl])-5-azacytosine: Synthesis and Antiviral Activity


Introduction

Acyclic nucleoside phosphonates (ANPs) represent a key class of antiviral nucleoside derivatives. One of the most promising drug candidates of this group is cidofovir, 1-((S)-[3-hydroxy-2-(phosphonomethoxy)propyl])-cytosine (HPMPC). This compound, in clinical practice approved for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, has strong activity against virtually all types of DNA viruses. However, a dose-limiting side effect of this drug is its nephrotoxicity. Furthermore, in contrast to other ANP drugs, cidofovir is given as an intravenous infusion, and orally applicable prodrugs are not available yet; their development is still in process. The unique activity of cidofovir combined with our effort for diminution of antiviral activity; the most active compound was found to be the hexadecyloxethyl ester. The relative configuration of the diastereoisomer trans-6 was determined using H,H-NOESY NMR.

Reaction of 1-((S)-[3-hydroxy-2-(phosphonomethoxy)propyl])-5-azacytosine (1) with dicyclohexylcarbodiimide and N,N,N-tricyclohexyl-4-morpholinocarboxamidine in dimethylformamide at elevated temperature afforded the corresponding cyclic phosphonate 2, that is, 1-(((5S)-2-hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl)methyl)-5-azacytosine. Compound 2 exerts strong in vitro activity against DNA viruses, comparable with activity of parent compound 1. Transformation of 2 to its tetrabutylammonium salt followed by reaction with alkyl or acyloxyalkyl halogenides enabled us to prepare a series of structurally diverse ester prodrugs: alkyl (octadecyl), alkenyl (erucyl), acyloxyalkyl (hexadecyloxethyl), and acyloxyalkyl (pivaloyloxymethyl) (3–6). The introduction of an alkyl, acyloxyalkyl, or acyloxyalkyl ester group to the molecule resulted in an increase of antiviral activity; the most active compound was found to be the hexadecyloxethyl ester 5. In our previous paper, we described the synthesis of cidofovir analogs containing as a base component 5-aza- and 6-azacytosine. Whereas the 6-aza derivative was virtually inactive, the 5-azacytosine analogue of cidofovir, 1-((S)-[3-hydroxy-2-(phosphonomethoxy)propyl])-5-azacytosine (HPMP-5-azaC, Figure 1), exerted strong activity against a broad spectrum of viruses: adenoviruses, poxviruses (vaccinia virus, cowpox virus, orf virus), herpes simplex (type 1 and 2) virus, varicella-zoster virus (VZV), and human cytomegalovirus (HCMV). Compared to cidofovir, its antiviral activity data [based on 50% effective concentration (EC50 values)] was similar or in some cases higher, and the antiviral selectivity index [ratio of 50% cytotoxic concentration (CC50) to EC50] was 2- to 16-fold higher than (S)-HPMPC.

Compound 1 has two negative charges in the molecule and, hence, its bioavailability is expected to be very low (similarly as for cidofovir). Generally, oral bioavailability of nucleoside phosphonates is improved by conversion of free phosphonic acids to neutral lipophilic esters. Thus, for example, adefovir, 9-[(2-phosphonomethoxy)ethyl]adenine (PMEA), is transformed to bis(pivaloyloxymethyl) ester prodrug adefovir dipivoxil (bis(POM)-PMEA), a compound approved for the treatment of chronic hepatitis B. Similarly, tenofovir, 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA), is clinically used as an anti-AIDS drug in the form of bis(isopropoxyxycarbonyloxethyl) ester, that is, tenofovir disoproxil (bis(POC)-PMPA). Oral bioavailability of this ester is >20% and antiviral effect in vitro is >100-fold higher than that of PMPA. During the past years, special attention has been paid to development of orally active prodrugs of HPMPC and its adenine counterpart, HPMPA, for their potential use against poxviruses including smallpox in case of a bioterrorist attack. Esterification of cidofovir can be performed at the level of the cyclic phosphonate. One possibility of such esterifications is represented by salicylate prodrugs. Another approach consists in preparation of lipid alkyl or alkoxyalkyl esters having about 20 atoms in the lipid chain. Introduction of various lipid alkoxyalkyl ester groups has recently been reported also for...
The reaction performed in dimethylformamide at elevated temperature afforded the desired 2-(hexadecyloxy)ethyl ester 5, but only in modest yield; due to mild reaction conditions, most starting compound 2 remained intact and could be recovered.

The attempts to prepare bis(acyloxy)alkyl ester prodrugs of 1 were inspired with methodology used for preparation of bis(POM)-PMEA consisting generally of the treatment of the appropriate chloromethyl (or iodomethyl) ether and N,N-dicyclohexyl-4-morpholinocarboxamide with free phosphonic acid. In contrast to PMEA, 1 treated under such conditions with chloromethyl pivalate afforded a complex nonseparable mixture of the expected bis(POM) ester 7 and both diastereomers of cyclic phosphonate 6 (Scheme 2) in a low overall yield. Yields and ratios of components were not reproducible. All effort for improvement of selectivity and yield of this reaction failed (e.g., substitution of chloromethyl pivalate with more reactive iodomethyl pivalate, use of starting phosphonate 1 in the form of lithium, pyridinium, or triethylammonium salt, variation of solvents, and temperature range). Therefore, we finally decided to develop the pivaloyloxymethyl ester prodrug not as bis(POM) ester 7 but similarly as in previous cases at the level of the cyclic phosphonate. Compound 2 was transformed to its tetrabutylammonium salt and then treated with chloromethyl pivalate in dry dioxane giving exclusively the desired POM ester 6 in very good yields (up 50% after all purification processes).

Esterification of 2 introduces new chiral center into the molecule resulting in formation of diastereoisomeric esters 3–6. The ratio of diastereoisomers was 5:2 to 3:2 in favor of the less polar diastereoisomer. These diastereoisomeric mixtures were used for basic in vitro antiviral evaluation. Because pharmacokinetic properties are generally in close relation to geometry of the molecule, it would be useful to get insight into configuration of the phosphorus chiral center. For this purpose, NMR spectroscopy was used as the method of choice due to the fact that esters 3–6 are difficult to separate and crystallize in order to obtain crystals suitable for X-ray analysis. The HPLC separation was successful only in the case of small amounts of the erucyl derivative 4 and the less polar major diastereoisomer of compound 6. Diastereoisomeric esters can accommodate two relative configurations trans and cis (Figure 2).

In the trans configuration, both azacytidine and OR moieties occupy equatorial positions on the six-membered ring in the chair conformation. On the other hand, cis configuration is used for azacytidine moiety in equatorial and OR group in axial position. The chair conformation can be unambiguously elucidated by inspection spin–spin coupling constants from 1H NMR spectrum (Table 1).

The relative configuration was determined from H,H-ROESY spectrum of less polar major diastereoisomer 6, for which NOE contacts between protons from OCH2O from the ester moiety and CH3P from the six-membered ring (trans configuration) or OCH2O ester moiety and CH3O from the six-membered ring (cis configuration) could be observed. Therefore, relative configuration of the less polar major diastereoisomer 6 was determined as trans due to NOE between protons from OCH2O and CH3P (see Supporting Information—H,H-ROESY of trans-6).

The relative configuration of other diastereoisomers 3–5 can be determined by comparison of their 31P (1H dec) NMR. 31P nucleus in less polar major diastereoisomers resonates at a higher magnetic field (10.63–11.43 ppm) than in polar minor diastereoisomers (12.56–13.60 ppm). Thus, it can be concluded that
less polar major diastereoisomers have trans configuration whereas more polar minor diastereoisomers occupy cis configuration.

**Biological Activity**

The antiviral activity of the different compounds was evaluated against various DNA viruses (Table 2), RNA viruses, and retroviruses (Table 3) in cell culture. The spectrum of activity of the cyclic form of 1-\((S)\)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (2) was comparable to that of HPMP-5-azaC (1) and the reference compounds HPMPC and cHPMPC. Compound 2 was able to inhibit the replication of poxviruses (vaccinia virus), and different herpesviruses, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient HSV-1 [acyclovir resistant (ACV\(^r\))] varicella-zoster virus (VZV), human cytomegalovirus (HCMV), and human herpesvirus 6 (HHV-6) with EC\(_{50}\) values in the range of 0.06–3.1 \(\mu\)g/mL. Compound 2 did not affect cell morphology or cell growth of HEL cells measured as, respectively, the minimum cytotoxic concentration (MCC) or the 50% cytostatic concentration (CC\(_{50}\)), up to a concentration of 100 \(\mu\)g/mL (highest concentration tested). This resulted in selectivity indices (ratio of CC\(_{50}\) to EC\(_{50}\)) varying from >47 (vaccinia virus) to >1500 (HCMV). The potency of the new triazine analogues 1 and 2 was comparable to that of HPMPC and cHPMPC; however, HPMP-5-azaC and cHPMP-5-azaC proved to be approximately 2-fold less cytostatic for HEL cells than HPMPC and cHPMPC, resulting in a superior selectivity. In the case of HHV-6, the cyclic form of 1-\((S)\)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (2) proved to be 5-fold (HHV-6A) and 13-fold (HHV-6B) less active than HPMP-5-azaC (1) in, respectively, human T-lymphoblast HSB-2 and MOLT-3 cells. Compound 2 proved to be more cytotoxic for MOLT-3 cells (MCC\(_{\text{33}}\)) than for HSB-2 cells (MCC\(_{\text{20}}\) \(\mu\)g/mL).

When the different ester prodrugs, that is, alkyl (octadecyl), alkenyl (erucyl), alkoxyalkyl (hexadecyloxyethyl), and acyloxyalkyl (pivaloyloxymethyl) (3–6), were evaluated, the hexadecyloxyethyl (5) emerged as the most active one, with EC\(_{50}\) values in the range of 0.003–0.008 \(\mu\)g/mL for HSV, HPMP-5-azaC (1) and cHPMP-5-azaC proved to be approximately 2-fold less cytostatic for HEL cells than HPMPC and cHPMPC, resulting in a superior selectivity. In the case of HHV-6, the cyclic form of 1-\((S)\)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (2) proved to be 5-fold (HHV-6A) and 13-fold (HHV-6B) less active than HPMP-5-azaC (1) in, respectively, human T-lymphoblast HSB-2 and MOLT-3 cells. Compound 2 proved to be more cytotoxic for MOLT-3 cells (MCC\(_{\text{33}}\)) than for HSB-2 cells (MCC\(_{\text{20}}\) \(\mu\)g/mL).

When the different ester prodrugs, that is, alkyl (octadecyl), alkenyl (erucyl), alkoxyalkyl (hexadecyloxyethyl), and acyloxyalkyl (pivaloyloxymethyl) (3–6), were evaluated, the hexadecyloxyethyl (5) emerged as the most active one, with EC\(_{50}\) values in the range of 0.003–0.008 \(\mu\)g/mL for HSV,
### Table 2. Antiviral and Cytotoxic Activity of the Compounds against DNA Viruses in Cell Culture

| Compound | HSV-1 (HEL) | HSV-2 (HEL) | VZV (OKA) | HHV-6A (HEL) | HHV-6B (HEL) | adenovirus (HELa) | vaccinia (HEL) | Cell morphology | Cytotoxicity (µg/mL)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>KOS</td>
<td>0.16 ± 0.16</td>
<td>0.22 ± 0.11</td>
<td>0.24 ± 0.11</td>
<td>0.32 ± 0.09</td>
<td>0.02 ± 0.01</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>KOS ACV</td>
<td>0.38 ± 0.55</td>
<td>0.71 ± 0.72</td>
<td>0.48 ± 0.25</td>
<td>0.61 ± 0.53</td>
<td>0.04 ± 0.03</td>
<td>200</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>Lyssavirus</td>
<td>0.02 ± 0.03</td>
<td>0.47 ± 0.91</td>
<td>0.66 ± 0.60</td>
<td>0.03 ± 0.02</td>
<td>0.06 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>G strain</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.05 ± 0.10</td>
<td>0.06 ± 0.16</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>OKA</td>
<td>0.02 ± 0.03</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.06</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>AD-169</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.06</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>HCMV</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.06</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>HHV-6B</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.06</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>1,18</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.06</td>
<td>0.07 ± 0.05</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>

* Effective concentration required to reduce virus-induced cytopathicity by 50%.

### Table 3. Antiviral and Cytotoxic activity of the Compounds against RNA Viruses and Retroviruses in Cell Culture

<table>
<thead>
<tr>
<th>Compound</th>
<th>EC50 (µg/mL)</th>
<th>Cytotoxicity cell morphology</th>
<th>Cytotoxicity cell growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1 (CEM)</td>
<td>(CEM)</td>
<td>(CEM)</td>
<td>(CHS)</td>
</tr>
<tr>
<td>HIV-2 (ROD)</td>
<td>(CEM)</td>
<td>(CEM)</td>
<td>(CHS)</td>
</tr>
<tr>
<td>MSV</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>VSV</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Coxsackie B3</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>RSV</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Parainfluenza-3</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Reovirus-1</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Sindbis</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Punta</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
<tr>
<td>Toro</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.02</td>
<td>0.04 ± 0.04</td>
</tr>
</tbody>
</table>

* Effective concentration required to reduce virus-induced cytopathicity by 50%.

---

*et al.*
\( \leq 0.0008 - \leq 0.0014 \mu g/mL \) for VZV, \( \leq 0.00014 - \leq 0.00038 \mu g/mL \) (HCMV), \( 0.008 - 0.037 \mu g/mL \) for HHV-6, and \( 0.037 \mu g/mL \) for vaccinia virus. This resulted in a 58- (vaccinia virus), 100- (mean for HSV strains), 123- (mean for VZV strains), to 250-fold (mean for HCMV strain) increase in antiviral activity when compared to cHPMP-5-azaC (2). Not only an improvement in the antiviral activity was observed for compound 5 but also an increase in selectivity. Thus, selectivity indices for virus), 1160 (HSV), \( 0.008 \) g prodrug (\( \text{EC}_{50} \)) showed activity against VZV (EC 50 ranging from 0.24 to 0.66 \( \mu g/mL \)) and vaccinia virus (EC 50 = 4.45 \( \mu g/mL \)) was observed. Despite the fact that the octadecyl ester (3) did not affect cell growth up to a concentration of 100 \( \mu g/mL \), it produced an alteration of cell morphology at a concentration \( \geq 20 \mu g/mL \).

The esterification of compound 2 to produce the erucyl prodrug (4) resulted in a loss of activity against vaccinia virus (EC 50 > 20 \( \mu g/mL \)) and no improvement or slight decrease in activity against HSV and VZV. However, compound 6 maintained a good potency against HCMV (EC 50 < 0.032 \( \mu g/mL \)). The pivaloyoxyethyl ester (6) showed EC 50 values equivalent to those of compound 2. A CCAA = 14 \( \mu g/mL \) was recorded for compound 6, resulting in a decrease in selectivity when compared to compound 2. As expected, akin to (S)-HPMPC (cidofovir) or its 5-azaC analogue, none of the compounds (2–6) showed activity against RNA viruses or retroviruses (Table 3).

Conclusion

In conclusion, the cyclic form of the new antiviral, 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azaC, was prepared, and general methodology for the preparation of its esters was worked out. The most active compound was found to be 2-(hexadecyloxy)ethyl ester of 1-[(S,S)-2-hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-ylmethylethyl]-5-azaC (5); the activity of ester produgs was decreasing in the order: 2-(hexadecyloxy)ethyl > pivaloyoxyethyl = octadecyl > erucyl. Not only was the 2-(hexadecyloxy)ethyl ester the most active compound it was also the most selective one.

Experimental Section

Unless stated otherwise, solvents were evaporated at 40 °C/2 kPa and compounds were dried at 13 Pa. Melting points were determined on a Kofler block and are uncorrected. Analytical TLC was performed on silica gel 60 F254 plates (Merck KGAa, Darmstadt, Germany); chromatographic systems are described in text. Preparative TLC was performed on silica gel UV-254 (30–60 μm, Service Laboratories of IJCB, Prague). Column chromatography was performed on silica gel 60 μm (Fluka). Reverse phase HPLC separations were performed on a Waters Delta 600 instrument with a Waters 2487 Dual λ Absorbance Detector using columns X Terra RP18 (5 μm, 3.9 × 150 mm, flow 1 mL/min, analytical column; 10 μm, 10 × 150 mm, flow 5 mL/min, preparative column) and Luna Phenomenex C-18 (10 μm, 21 × 250 mm, flow 12 mL/min, preparative column). \( ^1 \text{H} \) and \( ^{13} \text{C} \) NMR spectra were measured on a Bruker Avance 600 spectrometer (\( \text{H} \) at 600 MHz, \( ^{13} \text{C} \) at 151 MHz) or Bruker Avance 500 spectrometer (\( ^{1} \text{H} \) at 500 MHz, \( ^{13} \text{C} \) at 125.7 MHz) in CDCl 3 , D 2 O, DMSO-d 6 solutions (referenced to TMS, sodium 3-(trimethylsilyl)propane-1-sulfonic acid (DSS) or residual solvent signal). \( ^{31} \text{P} \) NMR spectra were measured on Bruker Avance 500 spectrometer (202.3 MHz in CDCl 3 ) using H 3 PO 4 as external standard. The numbering system for assignment of NMR signals is outlined in Figure 3. Mass spectra were measured on a ZAB-ESQ (VG Analytical) spectrometer using FAB (ionization with xenon, accelerating voltage 8 kV, glycerol matrix) or ESi technique.

Materials and Solvents. Most of the chemicals and ion-exchange resins (Dowex 1X2-400) were purchased from Sigma-Aldrich (Czech Republic). Dimethylformamide and dioxane were dried by distillation from CaH 2 (DMF in vacuo) and stored over molecular sieves 4 Å (DMF) or sodium (dioxane). Erucyl bromide and hexadecyloxyethyl bromide were prepared from the corresponding alcohols by the action of PBr 3 or carbon tetrabromide. For erucyl bromide, the method using carbon tetrabromide is more convenient to avoid cis–trans isomerization of the double bond.

Figure 3. General numbering scheme for assignment of NMR signals.

Esterification of 2 via Tetraethylammonium Salt. General Procedure. Methanolic tetraethylammonium hydroxide (1 M, 0.61 mL, 0.61 mmol) was added to a solution of 2 (161 mg, 0.60 mmol) in absolute methanol (50 mL), the mixture stirred for 10 min in ultrasound bath and evaporated. The residue was coevaporated with toluene (2 × 20 mL), dissolved in appropriate solvent (5 mL, dioxane for 3 and 6, DMF for 4 and 5), and stirred with alkyl bromide (1.5 mmol) or chloromethyl pivalate (5 mmol) at 95 – 100 °C for 3–6 h (TLC control). The reaction mixture was cooled to room temperature, diluted with methanol (2 mL) and evaporated. The residue was chromatographed on a column of silica gel (50 mL) in a system of chloroform – methanol (85:15) and the product obtained was purified by crystallization from methanol or HPLC separation.
Octadecyl Ester of 1-[[SS]-2-Hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]methyl]-5-azacytosine (3). Yield: 250 mg, 80% of a white solid after crystallization from methanol. Anal. (C_{29}H_{53}N_{4}O_{5}P) C, H, N, P. ESI-MS: 569.5 (15) (M+Na)^{+}, 523.1 (23) (M+H)^{+}. HRMS (QTOF): For C_{29}H_{53}N_{4}O_{5}P (M^{+}) calculated: 515.3362; found: 515.3382.

Major diastereoisomer (trans): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 12.67. Minor diastereoisomer (cis): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 12.56.

(Z)-Docos-13-enylyl Ester of 1-[[SS]-2-Hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]methyl]-5-azacytosine (4). Yield: 173 mg, 50% of a white solid (50 mg of 4a, 70 mg of 4b, 53 mg of diastereomeric mixture 4a). Anal. (C_{25}H_{48}N_{4}O_{6}P) C, H, N, P. ESI-MS: 569.5 (15) (M+Na)^{+}, 523.1 (23) (M+H)^{+}. HRMS (QTOF): For C_{25}H_{48}N_{4}O_{6}P (M^{+}) calculated: 515.3362; found: 515.3382. Major diastereoisomer (cis): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 10.77. Minor diastereoisomer (trans): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 10.63. Minor diastereoisomer (cis): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 12.67.

2-(Hexadecyloxy)ethyl Ester of 1-[[SS]-2-Hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]methyl]-5-azacytosine (5). Product crystallized from methanol, mother liquors additionally purified by preparative reverse phase HPLC (Luna Phenomenex column, gradient 10–90% methanol in 20 min elution of tetrabutylammonium), then 100% methanol elution of 5. Yield 172 mg, 53% of a white solid (50 mg of 5a, 70 mg of 5b, 53 mg of diastereomeric mixture 5a). Anal. (C_{29}H_{53}N_{4}O_{5}P) C, H, N, P. ESI-MS: 569.5 (15) (M+Na)^{+}, 523.1 (23) (M+H)^{+}. HRMS (QTOF): For C_{29}H_{53}N_{4}O_{5}P (M^{+}) calculated: 515.3362; found: 515.3382.

Major diastereoisomer (trans): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 10.57. Minor diastereoisomer (cis): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 10.77.

Pivaloyloxymethyl Ester of 1-[[SS]-2-Hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]methyl]-5-azacytosine (Cyclic POM–HPMP-azaC) (6). Purified by reverse phase HPLC (column Luna Phenomenex, 20% methanol isocratically). Yield 119 mg, 52% of a white solid foam. Anal. (C_{19}H_{34}N_{4}O_{10}P) C, H, N, P. Major diastereoisomer (trans): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 12.53. Minor diastereoisomer (cis): 31P (1H dec) NMR (202.3 MHz, CDCl_3): 10.77.

Reaction of 1 with Chloromethyl Pivalate. A suspension of 1 (275 mg; 1.83 mmol) was added and the mixture was stirred for 20 h. After cooling to room temperature, the mixture was diluted with water (10 mL) and applied onto a column of Dowex 1 (AcO^−, form 25), the column was eluted with acetonitrile (200 mL), followed by water (200 mL). The combined UV absorbing elutes were evaporated and the residue chromatographed on preparative silica gel plate (12 × 25 cm) in the system chloroform–methanol (85:15). Yield: 30 mg, 6.5%, white solid. The product was obtained as a mixture of two diastereoisomers (ratio 3:2). The unreacted starting compound was recovered from Dowex 1: the column was eluted first with 1 M acetic acid (250 mL) to remove some impurities and degradation products; the pure cyclic phosphonate 2 was eluted with 1 M formic acid. Appropriate fractions were evaporated, coevaporated with water (4 × 30 mL) and with absolute ethanol (50 mL), and dried in vacuo to give 150 mg (65%) of 2.

Antiviral Activity Assays. The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK^−) HSV-1 KOS strain resistant to ACV (ACV^−), herpes simplex virus type 2 (HSV-2) strains Lyons and G, varicella-zoster virus (VZV) strain Oka, TK-VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis, a clinical isolate of adenovirus type 2 (Ad2), human herpesvirus type 6 strain GP, and herpesvirus type 8 strain (HHV-8) strain Z29, vaccinia virus Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), Coxackie B4, Parainfluenza 3, Reovirus-1, Sindbis, Reovirus-1, Punta Toro, human immunodeficiency virus type 1 strain IIIB, human immunodeficiency virus type 2 strain ROD, and hepatitis C virus (HCV). The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human epithelial cells (HeLa) or human T-lymphoblasts HSB-2, and MOLT-3, according to previously established procedures.66 Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU). After a 1–2 h adsorption period, residual virus was removed, and the cell cultures were incubated in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC_{50} or concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%.

Inhibition of HIV-Induced Cytotoxicity in CEM Cells. The methodology for the anti-HIV assays has been described previously.37 Briefly, human CEM cell cultures (~3 × 10^6 cells mL^{-1})
were infected with ~100 CCID50 HIV-1 (IIIB) or HIV-2 (ROD) per mL and seeded in 200 μL-well microtiter plates, containing appropriate dilutions of the test compounds. After 4 days of incubation at 37 °C, syncytia cell formation was examined microscopically in the CEM cell cultures.

Inhibition of Moloney Murine Sarcoma Virus (MSV)-Induced Transformation of Murine C3H/3T Embryoblasts. The anti-MSV assay was performed as described previously.17 Murine C3H/3T embryoblast cells were seeded at 5 × 10^4 cells mL^-1 into 1-cm² wells of 48-well microplates. Then, 24 h later, the cell cultures were infected with 80 focus-forming units of MSV (prepared from tumors induced following intramuscular inoculation of 3-day-old NMRI mice with MSV, as described previously) for 90–120 min at 37 °C. The medium was then replaced by 1 mL of fresh medium containing various concentrations of the test compounds. After 6 days, transformation of the cell cultures was examined microscopically.

Cytotoxicity Assays. Cytotoxicity measurements were based on the inhibition of cell growth. HEL cells were seeded at a rate of 5 × 10^3 cells/well into 96-well microtiter plates and allowed to proliferate for 24 h. Then, medium containing different concentrations of the test compounds was added. After 3 days of incubation at 37 °C, the cell number was determined with a Coulter counter. The cytostatic concentration was calculated as the CC50, or the compound concentration required to reduce cell proliferation by 50% relative to the number of cells in the untreated controls. CC50 values were estimated from graphic plots of the number of cells (percentage of control) as a function of the concentration of the test compounds. Alternatively, cytoxicity of the test compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound concentration that caused a microscopically detectable alteration of cell morphology.

Acknowledgment. This study was performed as a research project of the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic # Z4 055 0506, and the Centre for New Antivirals and Antineoplastic Agents. We gratefully acknowledge the financial support of NIH (grant 1UC1 AI062540-01), the European Commission (René Descartes Prize-2001, grant HPAW-2002-100096), the Grant Agency of the Academy of Sciences of the Czech Republic: Prague, 2005; Vol. 7, pp 95–107.

Supporting Information Available: H-H ROErys of trans-6, copies of NMR spectra, 1H and 13C NMR spectral data of esters 3–5 and elemental analysis data. This material is available free of charge via the Internet at http://pubs.acs.org.

References


